Trials / Completed
CompletedNCT00379847
An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia
A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Cumberland Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | conivaptan | IV |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2006-09-25
- Last updated
- 2014-05-02
Locations
28 sites across 3 countries: United States, Israel, South Africa
Source: ClinicalTrials.gov record NCT00379847. Inclusion in this directory is not an endorsement.